Oramed Pharmaceuticals (ORMP) Gross Margin (2016 - 2025)

Oramed Pharmaceuticals (ORMP) posted Gross Margin of 0.65% for Q1 2025, down 99.35% on a QoQ basis from 100.0% in Q3 2019.

Oramed Pharmaceuticals (ORMP) Gross Margin (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals' Gross Margin history runs 5 years deep, the most recent figure standing at 0.65% for Q1 2025.

Quarterly Gross Margin changed N/A year-over-year to 0.65% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 0.65% (changed N/A YoY) and the FY2025 annual result came in at 0.65%, changed N/A from the prior year.
Gross Margin was 0.65% for Q1 2025 at Oramed Pharmaceuticals, down from 100.0% in the prior quarter.
Across five years, Gross Margin topped out at 0.65% in Q1 2025 and bottomed at 0.65% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	88.95%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	91.79%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	90.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Oramed Pharmaceuticals	170.25 Mn	170.25 Mn	-	-

Download Data